Chemoimmunotherapy of chronic lymphocytic leukemia

Constantine S. Tam; Michael J. Keating

doi:10.1016/j.beha.2007.02.004

Chemoimmunotherapy of chronic lymphocytic leukemia

Constantine S. Tam
, Michael J. Keating

Research output: Contribution to journal › Review Article › Research › peer-review

20 Citations (Scopus)

Abstract

The past two decades have seen a major paradigm shift in the therapy of chronic lymphocytic leukemia (CLL), with the treatment goal shifting from symptom palliation to the attainment of maximal disease control using the most effective frontline regimens available, thus prolonging survival and possibly leading to cure. The most potent therapeutic regimens developed to date include the chemoimmunotherapy combinations incorporating purine analogs and monoclonal antibodies. We review the evolution of modern chemoimmunotherapy for CLL, and discuss current research directions for further refining the potency of these regimens.

Original language	English
Pages (from-to)	479-498
Number of pages	20
Journal	Best Practice & Research: Clinical Haematology
Volume	20
Issue number	3
DOIs	https://doi.org/10.1016/j.beha.2007.02.004
Publication status	Published - Sept 2007
Externally published	Yes

Keywords

alemtuzumab
fludarabine
monoclonal antibody
purine analog
rituximab

Access to Document

10.1016/j.beha.2007.02.004

Cite this

@article{312b4f0fb0564cefbcbcf5ea208db476,

title = "Chemoimmunotherapy of chronic lymphocytic leukemia",

abstract = "The past two decades have seen a major paradigm shift in the therapy of chronic lymphocytic leukemia (CLL), with the treatment goal shifting from symptom palliation to the attainment of maximal disease control using the most effective frontline regimens available, thus prolonging survival and possibly leading to cure. The most potent therapeutic regimens developed to date include the chemoimmunotherapy combinations incorporating purine analogs and monoclonal antibodies. We review the evolution of modern chemoimmunotherapy for CLL, and discuss current research directions for further refining the potency of these regimens.",

keywords = "alemtuzumab, fludarabine, monoclonal antibody, purine analog, rituximab",

author = "Tam, \{Constantine S.\} and Keating, \{Michael J.\}",

year = "2007",

month = sep,

doi = "10.1016/j.beha.2007.02.004",

language = "English",

volume = "20",

pages = "479--498",

journal = "Best Practice \& Research: Clinical Haematology",

issn = "1521-6926",

publisher = "Elsevier",

number = "3",

}

TY - JOUR

T1 - Chemoimmunotherapy of chronic lymphocytic leukemia

AU - Tam, Constantine S.

AU - Keating, Michael J.

PY - 2007/9

Y1 - 2007/9

N2 - The past two decades have seen a major paradigm shift in the therapy of chronic lymphocytic leukemia (CLL), with the treatment goal shifting from symptom palliation to the attainment of maximal disease control using the most effective frontline regimens available, thus prolonging survival and possibly leading to cure. The most potent therapeutic regimens developed to date include the chemoimmunotherapy combinations incorporating purine analogs and monoclonal antibodies. We review the evolution of modern chemoimmunotherapy for CLL, and discuss current research directions for further refining the potency of these regimens.

AB - The past two decades have seen a major paradigm shift in the therapy of chronic lymphocytic leukemia (CLL), with the treatment goal shifting from symptom palliation to the attainment of maximal disease control using the most effective frontline regimens available, thus prolonging survival and possibly leading to cure. The most potent therapeutic regimens developed to date include the chemoimmunotherapy combinations incorporating purine analogs and monoclonal antibodies. We review the evolution of modern chemoimmunotherapy for CLL, and discuss current research directions for further refining the potency of these regimens.

KW - alemtuzumab

KW - fludarabine

KW - monoclonal antibody

KW - purine analog

KW - rituximab

UR - https://www.scopus.com/pages/publications/34547961559

U2 - 10.1016/j.beha.2007.02.004

DO - 10.1016/j.beha.2007.02.004

M3 - Review Article

C2 - 17707835

AN - SCOPUS:34547961559

SN - 1521-6926

VL - 20

SP - 479

EP - 498

JO - Best Practice & Research: Clinical Haematology

JF - Best Practice & Research: Clinical Haematology

IS - 3

ER -

Chemoimmunotherapy of chronic lymphocytic leukemia

Abstract

Keywords

Access to Document

Other files and links

Cite this